Added to YB: 2024-08-28
Pitch date: 2024-06-30
INSM [bullish]
Insmed Incorporated
+196.48%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Market Cap
$42.0B
Pitch Price
$66.45
Price Target
N/A
Dividend
N/A
EV/EBITDA
-43.68
P/E
-31.68
EV/Sales
91.89
Sector
Biotechnology
Category
growth
Show full summary:
Franklin Biotechnology Discovery Fund Portfolio Holding: Insmed Incorporated
INSM: Phase 3 success for rare lung disease drug brensocatib doubles stock. Significant reduction in pulmonary exacerbations for non-CF bronchiectasis. FDA application 4Q24, US launch mid-2025, Europe/Japan 1H 2026. Promising catalyst for growth.
Read full article (1 min)